Experience

Y-mAbs Therapeutics Agrees to Acquisition by SERB Pharmaceuticals

August 5, 2025

Cooley advised Y-mAbs Therapeutics, a commercial-stage biopharmaceutical company focused on the development and commercialization of antibody-based therapeutics for the treatment of cancer, on its definitive merger agreement with SERB Pharmaceuticals. Under the agreement, SERB will acquire Y-mAbs, including its lead commercial oncology asset, DANYELZA, in an all-cash transaction representing an equity value of approximately $412 million.

Read more

Related contacts

Bill Sorabella
Partner, New York
Bill Roegge
Partner, New York
Div Gupta
Partner, New York
Sarah Sellers
Partner, New York
Christophe Beauduin
Partner, New York
Megan Browdie
Partner, Washington, DC
Brad Goldberg
Partner, New York
Christopher Kimball
Partner, Washington, DC
Eileen Marshall
Partner, Washington, DC
Darah Protas
Partner, Washington, DC
Natasha Leskovsek
Of Counsel, Washington, DC
Julia Kim
Special Counsel, New York
Justin Kisner
Special Counsel, San Diego
MaryBeth Shreiner
Special Counsel, Reston
Karen Tsai
Special Counsel, Washington, DC
Amanda Weiss
Special Counsel, New York
Rajdeep Roger Bains
Associate, San Diego
Dayne Brown
Associate, New York
Norma Chayo Dichi
Associate, Washington, DC
Sharon Davidov
Associate, New York
Athina Gaki
Associate, Brussels
Kyle Hess
Associate, New York
Katie Kaufman
Associate, Boston
Nicollette R. Kirby
Associate, Washington, DC
Christopher Nickas
Associate, New York
Arda Can Tekin
Associate, New York
Shaun (Tianjie) Wang
Associate, New York

Related Practices & Industries

Inmagene Biopharmaceuticals Completes Merger With Ikena Oncology [UPDATED]

July 25, 2025

Cooley advised Inmagene Biopharmaceuticals, a privately held, global clinical-stage biotechnology company developing novel therapeutics for immunological and inflammatory diseases, on its definitive merger agreement with Ikena Oncology (Nasdaq: IKNA).

Read more

Related contacts

Lila Hope
Partner, Palo Alto
Rama Padmanabhan
Partner, San Diego
Patrick Loofbourrow
Partner, Singapore
Asa Henin
Partner, San Diego
Lindsey O'Crump
Associate, Washington, DC
Brittany K. Wightman
Associate, San Diego
Jiqiang Lin
Associate, New York
Leina Verrier
Associate, Santa Monica
Ross Eberly
Partner, Santa Monica
Stephanie Gentile
Partner, New York
Christopher Kimball
Partner, Washington, DC
Xander Lee
Partner, Santa Monica
Phil Mitchell
Partner, New York
Howard Morse
Senior Counsel, Washington, DC
Alessandra Murata
Partner, Palo Alto
Jean Park
Partner, New York
Aaron Pomeroy
Partner, Colorado
Michelle Garcia Schulman
Partner, Reston
Ellie Seber
Partner, Santa Monica
Marty Schenker
Senior Counsel , San Francisco
Mark Windfeld-Hansen
Senior Counsel, Palo Alto
Andrew Epstein
Special Counsel, Seattle
Stella Sarma
Partner, Brussels
Karen Tsai
Special Counsel, Washington, DC
Bin Wang
Special Counsel, Palo Alto
Robert Eisenbach
Of Counsel, San Francisco
Rajdeep Roger Bains
Associate, San Diego
Julia R. Brinton
Special Counsel, Washington, DC
Adrienne Beaudoin Deshmukh
Associate, Reston
Jeremy M. Exelbert
Associate, New York
Zack Gong
Associate, Shanghai
Rick Jantz
Associate, Santa Monica
Wyatt Kernell
Associate, Colorado
Rebeca Kinslow
Associate, San Diego
Hilda Li
Associate, Hong Kong
Lunga Su
Associate, Shanghai
Novak Topalovic
Associate, San Diego
Tania Soris
Associate, New York
Monica Xu
Special Counsel, Shanghai
Sai Yarramalla
Associate, Palo Alto
Andy Zachrich
Associate, San Francisco
Patricia Myers
Paralegal Specialist, Colorado
Jake Ironfield
Transactional Quantitative Analyst, New York

Related Practices & Industries

Inmagene Biopharmaceuticals Announces Merger With Ikena Oncology

December 23, 2024

Cooley advised Inmagene Biopharmaceuticals, a privately held, global clinical-stage biotechnology company developing novel therapeutics for immunological and inflammatory diseases, on its definitive merger agreement with Ikena Oncology (Nasdaq: IKNA).

Read more

Related contacts

Lila Hope
Partner, Palo Alto
Rama Padmanabhan
Partner, San Diego
Patrick Loofbourrow
Partner, Singapore
Asa Henin
Partner, San Diego
Lindsey O'Crump
Associate, Washington, DC
Brittany K. Wightman
Associate, San Diego
Jiqiang Lin
Associate, New York
Leina Verrier
Associate, Santa Monica
Ross Eberly
Partner, Santa Monica
Stephanie Gentile
Partner, New York
Christopher Kimball
Partner, Washington, DC
Xander Lee
Partner, Santa Monica
Phil Mitchell
Partner, New York
Howard Morse
Senior Counsel, Washington, DC
Alessandra Murata
Partner, Palo Alto
Jean Park
Partner, New York
Aaron Pomeroy
Partner, Colorado
Michelle Garcia Schulman
Partner, Reston
Ellie Seber
Partner, Santa Monica
Marty Schenker
Senior Counsel , San Francisco
Mark Windfeld-Hansen
Senior Counsel, Palo Alto
Andrew Epstein
Special Counsel, Seattle
Stella Sarma
Partner, Brussels
Karen Tsai
Special Counsel, Washington, DC
Bin Wang
Special Counsel, Palo Alto
Robert Eisenbach
Of Counsel, San Francisco
Rajdeep Roger Bains
Associate, San Diego
Julia R. Brinton
Special Counsel, Washington, DC
Adrienne Beaudoin Deshmukh
Associate, Reston
Jeremy M. Exelbert
Associate, New York
Zack Gong
Associate, Shanghai
Rick Jantz
Associate, Santa Monica
Wyatt Kernell
Associate, Colorado
Rebeca Kinslow
Associate, San Diego
Hilda Li
Associate, Hong Kong
Lunga Su
Associate, Shanghai
Novak Topalovic
Associate, San Diego
Tania Soris
Associate, New York
Monica Xu
Special Counsel, Shanghai
Sai Yarramalla
Associate, Palo Alto
Andy Zachrich
Associate, San Francisco
Patricia Myers
Paralegal Specialist, Colorado
Jake Ironfield
Transactional Quantitative Analyst, New York

Related Practices & Industries

Poseida Therapeutics Announces Agreement to Be Acquired by Roche for up to $1.5 Billion

November 26, 2024

Cooley advised Poseida Therapeutics, a clinical-stage allogeneic cell therapy and genetic medicines company advancing differentiated nonviral treatments for patients with cancer, autoimmune and rare diseases, on its merger agreement to be acquired by Roche at a price of $9 per share in cash at closing, plus a non-tradable contingent value right to receive up to an aggregate of $4 per share in cash, payable upon achievement of specified milestones. The price payable at closing represents a total equity value of up to $1.5 billion and a premium of approximately 215% to Poseida’s closing share price on November 25, 2024. Cooley previously represented Poseida in its initial public offering, equity and debt transactions, and collaboration agreements, including its collaboration agreement with Roche.

Read more

Related contacts

Rowook Park
Partner, San Diego
Barbara Borden
Senior Counsel, San Diego
Julia Kim
Special Counsel, New York
Rajdeep Roger Bains
Associate, San Diego
Josh Himmelstern
Associate, San Diego
Elaine Huang
Associate, Palo Alto
Anne Luquette
Associate, San Francisco
Allie Pilmer
Associate, San Diego
Tom Coll
Partner, San Diego
Kenneth Krisko
Partner, Reston
Edmond Lay
Partner, San Diego
John Forrest
Associate, Boston
Jenny Ge
Associate, Santa Monica
Peter Adams
Partner, San Diego
Michael Bergmann
Partner, Washington, DC
Megan Browdie
Partner, Washington, DC
Ross Eberly
Partner, Santa Monica
Todd Gluth
Partner, San Diego
Christopher Kimball
Partner, Washington, DC
Alessandra Murata
Partner, Palo Alto
Jeffrey J. Tolin
Partner, New York
Robert Eisenbach
Of Counsel, San Francisco
Maricel Mojares-Moore
Special Counsel, San Francisco
Dillon Martinson
Special Counsel, Washington, DC
Stella Sarma
Partner, Brussels
Natasha Leskovsek
Of Counsel, Washington, DC
Alexandria Ashour
Associate, San Diego
Navya Dasari
Associate, New York
Nicollette R. Kirby
Associate, Washington, DC
Allison Kutner
Associate, New York
Calvin Lee
Associate, New York
Calvin Lee
Associate, New York
Breanna Qin
Associate, Palo Alto
Shelby Saunders
Associate, New York
Shaun (Tianjie) Wang
Associate, New York
Colleen R. Wellington-Caban
Associate, Washington, DC
Jack Whitaker
Associate, San Diego
Anna Anderson
Paralegal Specialist, London
Novak Topalovic
Associate, San Diego

Related Practices & Industries

Nerio Therapeutics Sells to Boehringer Ingelheim for up to $1.3 Billion

July 29, 2024

Cooley advised Nerio Therapeutics, a drug discovery and development company focused on phosphatases, a notoriously difficult class of potentially high-value therapeutic protein targets, on its sale to Boehringer Ingelheim, a biopharmaceutical company active in both human and animal health, for up to $1.3 billion.

Read more

Related contacts

Rama Padmanabhan
Partner, San Diego
Charity Williams
Partner, San Diego
Rajdeep Roger Bains
Associate, San Diego
Ken Rollins
Partner in Charge – San Diego, San Diego
Alessandra Murata
Partner, Palo Alto
Tony P. Guan
Associate, Santa Monica
Allison Kutner
Associate, New York
Natasha Leskovsek
Of Counsel, Washington, DC
Phil Mitchell
Partner, New York
Jeffrey J. Tolin
Partner, New York
Ross Eberly
Partner, Santa Monica
Dylan Kornbluth
Associate, San Diego
Joanna Zhang
Associate, San Diego
Allie Pilmer
Associate, San Diego
Howard Morse
Senior Counsel, Washington, DC
Sharon Connaughton
Special Counsel, Washington, DC
Katie Kissner
Quantitative Analyst, San Francisco

Related Practices & Industries

View more

Admissions and credentials

California

Rankings and accolades

Winner, San Diego Business Journal: 40 Next Top Business Leaders Under Forty (2024)